![Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates | Journal for ImmunoTherapy of Cancer Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/9/e003122/F2.large.jpg)
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates | Journal for ImmunoTherapy of Cancer
![Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017) Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)](https://erc.bioscientifica.com/view/journals/erc/24/9/images/large/full-475fig2.jpeg)
Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)
![Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753420397969-gr1.jpg)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
![a) Median progression-free survival (PFS) to second-line (SL) therapy.... | Download Scientific Diagram a) Median progression-free survival (PFS) to second-line (SL) therapy.... | Download Scientific Diagram](https://www.researchgate.net/publication/330793879/figure/fig1/AS:721488437051394@1549027656209/a-Median-progression-free-survival-PFS-to-second-line-SL-therapy-b-The-median.png)
a) Median progression-free survival (PFS) to second-line (SL) therapy.... | Download Scientific Diagram
![Median overall survival (OS) and progression-free survival (PFS) in a... | Download Scientific Diagram Median overall survival (OS) and progression-free survival (PFS) in a... | Download Scientific Diagram](https://www.researchgate.net/publication/339177178/figure/fig4/AS:857392841490434@1581429791443/Median-overall-survival-OS-and-progression-free-survival-PFS-in-a-population-based.png)
Median overall survival (OS) and progression-free survival (PFS) in a... | Download Scientific Diagram
![JCM | Free Full-Text | A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation | HTML JCM | Free Full-Text | A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation | HTML](https://www.mdpi.com/jcm/jcm-08-00952/article_deploy/html/images/jcm-08-00952-g001.png)
JCM | Free Full-Text | A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation | HTML
![Progression-free survival (median PFs, 206 days; 95% ci, 153-259) and... | Download Scientific Diagram Progression-free survival (median PFs, 206 days; 95% ci, 153-259) and... | Download Scientific Diagram](https://www.researchgate.net/publication/273896949/figure/fig2/AS:613943508746271@1523386947939/Progression-free-survival-median-PFs-206-days-95-ci-153-259-and-overall-survival.png)
Progression-free survival (median PFs, 206 days; 95% ci, 153-259) and... | Download Scientific Diagram
![Overall survival and progression-free survival. The median follow-up... | Download Scientific Diagram Overall survival and progression-free survival. The median follow-up... | Download Scientific Diagram](https://www.researchgate.net/publication/359398730/figure/fig1/AS:1136621336444946@1648003052778/Overall-survival-and-progression-free-survival-The-median-follow-up-time-was-131-range.png)
Overall survival and progression-free survival. The median follow-up... | Download Scientific Diagram
![Kaplan–Meier plot of progression-free survival Median progression-free... | Download Scientific Diagram Kaplan–Meier plot of progression-free survival Median progression-free... | Download Scientific Diagram](https://www.researchgate.net/publication/331026250/figure/fig2/AS:734407153418240@1552107718315/Kaplan-Meier-plot-of-progression-free-survival-Median-progression-free-survival-PFS-for.jpg)
Kaplan–Meier plot of progression-free survival Median progression-free... | Download Scientific Diagram
![Kaplan-Meier analysis of (a) progression-free survival (PFS); and (b)... | Download Scientific Diagram Kaplan-Meier analysis of (a) progression-free survival (PFS); and (b)... | Download Scientific Diagram](https://www.researchgate.net/publication/343894797/figure/fig1/AS:938411976298498@1600746258580/Kaplan-Meier-analysis-of-a-progression-free-survival-PFS-and-b-overall-survival.png)
Kaplan-Meier analysis of (a) progression-free survival (PFS); and (b)... | Download Scientific Diagram
![Percentage Progression-free survival and overall survival on treatment.... | Download Scientific Diagram Percentage Progression-free survival and overall survival on treatment.... | Download Scientific Diagram](https://www.researchgate.net/publication/331028577/figure/fig4/AS:941421343305740@1601463747636/Percentage-Progression-free-survival-and-overall-survival-on-treatment-a-Median-PFS-is.png)
Percentage Progression-free survival and overall survival on treatment.... | Download Scientific Diagram
![Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology](https://www.jcancer.org/v10/p3717/jcav10p3717g002.jpg)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
![Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-28410-9/MediaObjects/41467_2022_28410_Fig1_HTML.png)
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
![Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-020-01042-y/MediaObjects/41375_2020_1042_Fig2_HTML.png)
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
![Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/4/e002114/F2.large.jpg)
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
![Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive](https://archive.cancerworld.net/wp-content/uploads/2015/10/Correlation-by-itself-does-not-imply-surrogacy.jpg)